Small-cell lung cancer (SCLC) transformation has been considered to be the most common phenotypic change in EGFR-mutant non-small-cell lung cancers (NSCLCs) during disease progression under treatment with earlier-generation EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.